Substance / Medication

Nicotinamide

Overview

Active Ingredient
niacinamide
RxNorm CUI
7405

Indications

Dialyvite 3000 is a prescription folic acid supplement with additional nutrients indicated for use in improving the nutritional status of renal dialysis patients.

Labeler: Hillestad Pharmaceuticals USAUpdated: 2027-01-27T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

This product is contraindicated in patients with known hypersensitivity to any of the ingredients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

20 trials linked to this intervention

20
Total Trials
0
Recruiting
10
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models.
Qader Musaab Abdulrazzaq, Hosseini Leila, Abolhasanpour Nasrin et al. · BMC Neurosci · 2025
PMID: 40033213Meta-AnalysisFull text (PMC)
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Prokopidis Konstantinos, Moriarty Frank, Bahat Gülistan et al. · J Cachexia Sarcopenia Muscle · 2025
PMID: 40275690Meta-AnalysisFull text (PMC)
The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis.
Tosti Giulio, Pepe Francesca, Gnagnarella Patrizia et al. · Nutrients · 2023
PMID: 38201930Meta-AnalysisFull text (PMC)
Protective Effects of Nicotinamide Adenine Dinucleotide and Related Precursors in Alzheimer's Disease: A Systematic Review of Preclinical Studies.
Hosseini Leila, Mahmoudi Javad, Pashazadeh Fariba et al. · J Mol Neurosci · 2021
PMID: 33907963Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nicotinamide (substance)
SNOMED CT
173196005
UMLS CUI
C0028027
RxNorm CUI
7405
Labeler
Hillestad Pharmaceuticals USA

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

5
Conditions
1
Biomarkers
0
Specialists
0
Symptoms
20
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.